Shanghai Xudong Haipu Pharmaceutical Co., Ltd.
As of 18 November 2026, for the company name Shanghai Xudong Haipu Pharmaceutical Co., Ltd. as recorded, the chemical-drug catalogue lists 31 active records with this name as holder; 22 active API registrations list this name as first registered company.
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/18.
Drug filings
38 acceptance records as first applicant, grouped into 23 source drug names. Source data as of 2026/11/18.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
Gadopentetic Acid Dimeglumine Salt Injection 1 records · Latest accepted 2026/08/17
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2601560 | Supplement | 2026/08/17 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
Fluorouracil Injection 3 records · Latest accepted 2026/07/16
Supplement · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2601362 | Supplement | 2026/07/16 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHB2151094 | Supplement | 2021/12/16 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHB2150651 | Supplement | 2021/06/08 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
Esomeprazole Sodium for Injection 1 records · Latest accepted 2025/06/14
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2501211 | Supplement | 2025/06/14 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd.; Shanghai Fu Dan Fu Hua Pharma Co., Ltd. romanized | CDE ↗ |
硫酸特布他林雾化吸入用溶液 · No verified English name 1 records · Latest accepted 2025/05/30
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2501938 | Generic | 2025/05/30 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
Diazepam Injection 1 records · Latest accepted 2025/04/11
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2550170 | Supplement | 2025/04/11 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
Iohexol Injection 3 records · Latest accepted 2025/01/17
Supplement · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2550061 | Supplement | 2025/01/17 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd.; Yuan Da Pharmaceuticals (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| CYHB2550060 | Supplement | 2025/01/17 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd.; Yuan Da Pharmaceuticals (Zhongguo) Co., Ltd. romanized | CDE ↗ |
| CYHB2550059 | Supplement | 2025/01/17 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd.; Yuan Da Pharmaceuticals (Zhongguo) Co., Ltd. romanized | CDE ↗ |
Dobutamine Hydrochloride Injection 3 records · Latest accepted 2024/12/31
Supplement · 1Generic · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2402255 | Supplement | 2024/12/31 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHS2102338 | Generic | 2021/12/31 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHS2102337 | Generic | 2021/12/31 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
Amiodarone Hydrochloride Injection 3 records · Latest accepted 2024/11/13
Supplement · 2Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2401882 | Supplement | 2024/11/13 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHB2401880 | Supplement | 2024/11/13 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHS2100105 | Generic | 2021/01/27 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
Sodium Ibandronate Injection 3 records · Latest accepted 2024/06/21
Generic · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2401865 | Generic | 2024/06/21 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHS2401864 | Generic | 2024/06/21 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHS2401863 | Generic | 2024/06/21 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
Dexrazoxane for Injection 1 records · Latest accepted 2024/06/12
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2401772 | Generic | 2024/06/12 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
Phentolamine Mesilate Injection 1 records · Latest accepted 2024/04/17
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2450246 | Supplement | 2024/04/17 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
Flumazenil Injection 2 records · Latest accepted 2023/11/24
Generic · 2
Magnesium Sulfate Injection 2 records · Latest accepted 2023/11/09
Supplement · 2
氢溴酸加兰他敏注射液 · No verified English name 3 records · Latest accepted 2023/10/28
Supplement · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2302376 | Supplement | 2023/10/28 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHB2300514 | Supplement | 2023/03/10 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
| CYHB2102447 | Supplement | 2021/12/27 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
Neostigmine Methylsulfate Injection 2 records · Latest accepted 2023/09/25
Generic · 2
Nicorandil for Injection 1 records · Latest accepted 2023/07/05
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2301804 | Generic | 2023/07/05 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
Macitentan Tablets 1 records · Latest accepted 2023/01/01
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2202176 | Generic | 2023/01/01 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
Pentoxifylline Injection 1 records · Latest accepted 2022/09/27
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2201620 | Generic | 2022/09/27 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
Levosimendan Injection 1 records · Latest accepted 2022/01/18
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2200110 | Generic | 2022/01/18 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
Tramadol Hydrochloride Injection 1 records · Latest accepted 2021/12/29
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2151123 | Supplement | 2021/12/29 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
Digoxin Injection 1 records · Latest accepted 2021/07/15
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2101427 | Generic | 2021/07/15 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
Warfarin Sodium Tablets 1 records · Latest accepted 2021/06/25
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2101348 | Generic | 2021/06/25 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
Succinylcholine Chloride Injection 1 records · Latest accepted 2021/01/15
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2150033 | Supplement | 2021/01/15 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
Changes in the last 90 days
5 events from 2026/08/22 to 2026/11/19. CDE data as of 2026/11/18; NMPA data as of 2026/11/19.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
Marketing application approved: 1 applicationNo longer listed under review: 1 applicationNotification delivery: 3 applications
- 2026/11/18Marketing application approved
硫酸特布他林吸入溶液 · No verified English name
CYHS2501938 · 国药准字H20266605
Fact date: 2026/11/18 · Publication date: 2026/11/19 · Date added to this site: 2026/11/19
View source · Table row 53 ↗ - 2026/10/31No longer listed under review
硫酸特布他林雾化吸入用溶液 · No verified English name
CYHS2501938
Fact date: 2026/10/31 · Date added to this site: 2026/10/31
Accepted: 2025/05/30
no longer on the CDE under-review list as of the data cut-off; the review / approval outcome is to be checked
View source ↗ - 2026/10/28Notification delivery
Sodium Ibandronate Injection
CYHS2401865
Fact date: 2026/10/28 (Publication date) · Publication date: 2026/10/28 · Date added to this site: 2026/11/03
Notification delivered; the specific outcome remains to be checked.
View source · Table row 7 ↗ - 2026/10/28Notification delivery
Sodium Ibandronate Injection
CYHS2401864
Fact date: 2026/10/28 (Publication date) · Publication date: 2026/10/28 · Date added to this site: 2026/11/03
Notification delivered; the specific outcome remains to be checked.
View source · Table row 6 ↗ - 2026/10/28Notification delivery
Sodium Ibandronate Injection
CYHS2401863
Fact date: 2026/10/28 (Publication date) · Publication date: 2026/10/28 · Date added to this site: 2026/11/03
Notification delivered; the specific outcome remains to be checked.
View source · Table row 5 ↗
Under review
2 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/18.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Gadopentetic Acid Dimeglumine Salt Injection | CYHB2601560 | Supplement | 2026/08/17 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
| Fluorouracil Injection | CYHB2601362 | Supplement | 2026/07/16 | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
Catalogue holder records
31 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/18. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | Approval number | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Diazepam Injection | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H31021864 | 2026/06/16 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Dobutamine Hydrochloride Injection | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H20269088 | 2026/04/13 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Iohexol Injection | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Yuan Da Pharmaceuticals (Zhongguo) Co., Ltd. romanized | 国药准字H20084036 | 2026/04/10 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Iohexol Injection | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Yuan Da Pharmaceuticals (Zhongguo) Co., Ltd. romanized | 国药准字H20084038 | 2026/04/10 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Iohexol Injection | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Yuan Da Pharmaceuticals (Zhongguo) Co., Ltd. romanized | 国药准字H20084037 | 2026/04/10 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Dexrazoxane for Injection | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H20255875 | 2025/11/04 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Flumazenil Injection | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H20254167 | 2025/05/13 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Flumazenil Injection | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H20254168 | 2025/05/13 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Phentolamine Mesilate Injection | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H31020589 | 2025/04/07 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Neostigmine Methylsulfate Injection | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H20253701 | 2025/03/25 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Neostigmine Methylsulfate Injection | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H20253700 | 2025/03/25 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Nicorandil for Injection | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H20249843 | 2024/12/25 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Magnesium Sulfate Injection | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H20247223 | 2024/09/25 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Pentoxifylline Injection | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H20244189 | 2024/06/28 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Macitentan Tablets | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H20243902 | 2024/06/04 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Dobutamine Hydrochloride Injection | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H20234366 | 2023/10/24 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Levosimendan Injection | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H20234115 | 2023/09/05 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Warfarin Sodium Tablets | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H20233268 | 2023/03/15 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Digoxin Injection | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H20233269 | 2023/03/15 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Tramadol Hydrochloride Injection | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H20023785 | 2023/02/20 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Fluorouracil Injection | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H31020593 | 2023/01/10 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Penehyclidine Hydrochloride Injection | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H20223885 | 2022/11/30 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Succinylcholine Chloride Injection | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H31020599 | 2022/09/19 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Fluorouracil Injection | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H20217031 | 2022/07/04 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Haloperidol Lactate Injection | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H31020665 | 2022/07/04 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Amiodarone Hydrochloride Injection | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H20223372 | 2022/06/07 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Bromhexine Hydrochloride Injection | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H31022703 | 2021/09/18 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Terbutaline Sulfate Injection | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H20213722 | 2021/09/13 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Metoprolol Tartrate Tablets | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H31020783 | 2021/06/18 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Milrinone Injection | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H20203726 | 2020/12/29 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Captopril Tablets | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | 国药准字H31020564 | 2020/01/07 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
22 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/18.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| 氟哌利多 · No verified English name | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Y20240000781 | A | 2026/02/14 | CDE ↗ |
| 甲硫酸新斯的明 · No verified English name | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Y20230000442 | A | 2024/12/13 | CDE ↗ |
| 己酮可可碱 · No verified English name | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Y20220000799 | A | 2024/05/30 | CDE ↗ |
| 左西孟旦 · No verified English name | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Y20210001119 | A | 2023/08/29 | CDE ↗ |
| 盐酸多巴酚丁胺 · No verified English name | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Y20210001064 | A | 2025/07/09 | CDE ↗ |
| 硫酸特布他林 · No verified English name | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Y20190008483 | A | 2025/03/15 | CDE ↗ |
| 氢溴酸加兰他敏 · No verified English name | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Y20190007696 | A | 2024/12/14 | CDE ↗ |
| 尼可地尔 · No verified English name | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Y20190007216 | A | 2024/06/13 | CDE ↗ |
| 盐酸雷莫司琼 · No verified English name | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Y20190005678 | A | — | CDE ↗ |
| 羟丁酸钠 · No verified English name | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Y20190002563 | A | — | CDE ↗ |
| 塞替派 · No verified English name | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Y20190002562 | A | 2025/01/17 | CDE ↗ |
| 亚硝酸异戊酯 · No verified English name | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Y20190002561 | A | — | CDE ↗ |
| 盐酸氮芥 · No verified English name | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Y20190001774 | A | 2025/01/17 | CDE ↗ |
| 甲磺酸酚妥拉明 · No verified English name | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Y20190001773 | A | 2025/02/09 | CDE ↗ |
| 门冬氨酸钙 · No verified English name | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Y20190001633 | A | 2024/11/19 | CDE ↗ |
| 氯化琥珀胆碱 · No verified English name | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Y20190001632 | A | 2024/11/19 | CDE ↗ |
| 去乙酰毛花苷 · No verified English name | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Y20190001496 | A | 2024/12/14 | CDE ↗ |
| 华法林钠 · No verified English name | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Y20190001495 | A | 2024/12/14 | CDE ↗ |
| 单硝酸异山梨酯 · No verified English name | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Y20190001494 | A | 2024/12/14 | CDE ↗ |
| 盐酸戊乙奎醚 · No verified English name | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Y20190000786 | A | 2024/05/29 | CDE ↗ |
| 盐酸妥拉唑林 · No verified English name | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Y20170001489 | I | — | CDE ↗ |
| 米力农 · No verified English name | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | Y20170001439 | A | 2023/10/19 | CDE ↗ |
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
1 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/18.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Quetiapine Fumarate Tablets | JTH2600102 | Not stated by source | 2026/05/27 | Klocke Pharma-Service GmbH; CHEPLAPHARM Arzneimittel GmbH; Shanghai Xudong Haipu Pharmaceutical Co., Ltd. | CDE ↗ |
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/18 · Current coverage may be incomplete
- Chemical-drug catalogue
- Last successful update: 2026/11/18
- API registrations
- Last successful update: 2026/11/18
- NMPA drug delivery notices
- Last successful update: 2026/11/19
Loaded notices dated 2026-11-05 to 2026-11-19; 0 notices not yet loaded. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.